Ernesto Abel-Santos

Ernesto Abel-Santos is a Professor of Biochemistry at the University of Nevada, Las Vegas, specializing in bacterial spore germination and bio-organic chemistry. His research focuses on medical countermeasures against bioterrorism threats and healthcare-associated infections.

• Education: Ph.D. in Bioorganic Chemistry from Washington School of Medicine, St. Louis, Missouri
• Education: B.S. in Chemistry from Universidad Autónoma de Santo Domingo, Dominican Republic

Abel-Santos' lab investigates Clostridium difficile (C-diff) and Bacillus anthracis (anthrax) spore germination mechanisms. His team develops nucleoside inhibitors to control antibiotic-resistant infections and co-founded Able Therapeutics LLC to commercialize preventative treatments for C-diff. This startup targets a growing U.S. epidemic, with C-diff causing 500,000 annual infections and 20,000 deaths.

His research spans bio-organic chemistry, enzymology, and microbiology, with applications in hospital infection control, biodefense, and agricultural health. Recent studies explore bacterial impacts on chickens and honeybees, reflecting broader implications of spore biology. Collaborative efforts focus on developing spore-targeted therapeutics and disinfection strategies.

While not explicitly listing scientific awards, Abel-Santos' work has garnered media attention in outlets like Science Times and Interesting Engineering, highlighting his contributions to combating gastrointestinal infections and improving sanitation protocols. He frequently advises on germ control best practices, particularly during the pandemic.